Comparison of Outcomes among Chronic Kidney Disease V Patients with COVID-19 at the National Kidney and Transplant Institute: A Retrospective Cohort Study
Table 2
Baseline laboratory and radiologic findings of CKD V patients with COVID-19 (n = 436).
All patients (n = 436) Median [IQR]
HD (n = 297) Median [IQR]
PD (n = 103) Median [IQR]
Dialysis initiation (n = 35) Median [IQR]
value
WBC count (in x10^9/L)
8.68 [IQR: 6–12.75]
8.45 [IQR:5.75–12.14]
8.94 [IQR:6.75–12.5]
11.23 [IQR:6.83–18.24]
0.0561a
Absolute lymphocyte count (in cells/microL)
948.68 [IQR:622.08–1277.82]
949.98 [IQR:609.03–1264.56]
930.95 [IQR:652.80–1302.84]
1002.50 [IQR:590.40–1317.84]
0.8442a
Hemoglobin (in g/dl)
9.2 [IQR:7.8–10.9]
9.2 [IQR:7.7–10.9]
8.9 [IQR:7.8–9.9]
10.85 [IQR:9.3–12.3]
0.0019a
Platelet (in 10 ^ 3/uL)
231 [IQR:168–305]
220 [IQR:156–278]
289 [IQR:206–373]
229 [IQR:179–329]
0.0001a
Sodium (in meq/L)
136 [IQR:132–140]
137 [IQR:134–141]
135 [IQR:131–140]
131.5 [IQR:127–135]
0.0001a
Potassium (in meq/L)
4.7 [IQR:4–5.7]
5 [IQR:4.2–5.9]
4.2 [IQR:3.5–5.1]
4.5 [IQR:3.8–5.2]
0.0001a
Corrected calcium (in mg/dl)
7.9 [IQR:7.2–8.5]
8 [IQR:7.3–8.6]
7.6 [IQR:6.9–8.4]
7.8 [IQR:7.2–8.6]
0.0067a
Albumin (in g/dl)
3.4 [IQR:3–3.8]
3.5 [IQR:3.1–3.9]
3 [IQR:2.35–3.45]
3.65 [IQR:2.8–4]
0.0001a
Ferritin (in ng/ml)
1253.60 [IQR:575.8–2322.4]
1275.35 [IQR:561.9–2381.2]
1189.15 [IQR:624.6–1824.6]
1339.1 [IQR:981.92–2369.65]
0.6630a
LDH (in IU/L)
367 [IQR:273–516]
391 [IQR:282.5–540]
344 [IQR:257–431]
315.5 [IQR:225.5–422.5]
0.0307a
hs-CRP (in mg/L)
78.60 [IQR:31.14]
88.9 [IQR:35.76–155.85]
55.61 [IQR:14.08–107]
77.38 [IQR:34.42–106.36]
0.0299a
Procalcitonin (in ng/ml)
1.93 [IQR:0.54–11.15]
3.26 [IQR:0.78–14.98]
0.75 [IQR:0.42–2.44]
1.57 [IQR:0.18–4.37]
0.0008a
Normal
61(14)
36(12)
16(16)
9(27)
0.097b
Single-lobe pneumonia
118(28)
75(26)
31(30)
12(36)
Multilobar pneumonia
208(49)
153(52)
46(45)
9(27)
Interstitial/diffuse bilateral pneumonia
41(10)
29(10)
9(9)
3(9)
aMann–Whitney U test was used; bchi-square test was used.
